Melanoma Coverage from Every Angle
Advertisement
Advertisement

Recent News

Preclinical Study Explores BH3 Mimetic Combinations in Melanoma
‘Priming’ Patients With Advanced Melanoma for Retreatment With Checkpoint Inhibitors
Two-Year Survival Results With Neoadjuvant T-VEC in Resectable Melanoma
SMR 2019: T-VEC Plus Ipilimumab in Advanced Melanoma
SMR 2019: Tumor-Infiltrating Lymphocyte Therapy for Refractory Metastatic Melanoma
SMR 2019: Nivolumab Plus Ipilimumab and Nivolumab Alone in Advanced Melanoma
SMR 2019: Vaccine Under Study to Prevent Recurrence in High-Risk Advanced Melanoma
ABC Trial: Nivolumab Plus Ipilimumab for Melanoma Brain Metastases
Triplet Regimen for BRAF-Mutated Metastatic Melanoma
SITC 2019: Adding IL-2 Agonist to Nivolumab in Metastatic Melanoma
SITC 2019: Adenovirus Plus Pembrolizumab in Resistant Melanoma
Nivolumab and Ipilimumab in Melanoma: OpACIN Trial Follow-up
Can Second Opinions From Pathologists Improve Melanoma Diagnoses?
The Wistar Institute Awarded $12.5M Grant for Melanoma Targeted Therapies
ESMO 2019: Neoadjuvant Talimogene Laherparepvec in Advanced Resectable Melanoma
New $1M Grants for Research on Melanoma Metastasis
ESMO 2019: Cobimetinib Plus Atezolizumab Versus Pembrolizumab in BRAF V600 Wild-Type Melanoma
ESMO 2019: Update From CheckMate 238 of Nivolumab Versus Ipilimumab in Advanced Melanoma
ESMO 2019: 5-Year Survival Data on Nivolumab Plus Ipilimumab in Advanced Melanoma
Novel Vaccine for Melanoma Is Focus of Preclinical Research
Potential of Novel Combination Under Study in Metastatic Mucosal Melanoma
Cryopreserved Lifileucel in Advanced Refractory Metastatic Melanoma
Quality Care 2019: Effect of Interdisciplinary Shared Medical Appointments on Melanoma Survivors
Can Targeting Brain Pathways Inhibit Brain Metastasis in Patients With Melanoma?
Triple-Drug Therapy Under Study in BRAF-Mutant Melanoma
Does Combination Immunotherapy Improve Survival in Metastatic Uveal Melanoma?
Epacadostat With Pembrolizumab in Advanced Melanoma
Genetics + Environment: Evidence of Synergy in Increasing Skin Cancer Risk
Bempegaldesleukin With Nivolumab Granted Breakthrough Therapy Designation in Melanoma
Assessing Anti–PD-1 Therapy Efficacy After Complete Response in Melanoma
COLUMBUS Trial: Updated Outcomes With BRAF/MEK Inhibitors in Advanced Melanoma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.